Current Clinical Trials

Summary

This quality improvement project aims to evaluate the clinical impact and cost implications of immunotherapy initiation or continuation in the inpatient setting, focusing on patient outcomes, adverse events, and the variability in response times to immunotherapy. A retrospective chart review will be performed to identify adult patients who received anti-cancer immunotherapy either for treatment initiation or continuation in the hospital setting from January 1, 2022 to December 31, 2024.

Official Title

Evaluating the Implications of Initiating Immunotherapy Anti-cancer Treatment in the Inpatient Setting on Patient Outcomes, Treatment Tolerance, and Drug Costs